Drugs / NTX-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05041543 | Mar → Jun 2021 | — | Pinotbio, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-12-23 | Pinotbio, Inc. | Regulatory 피노바이오, 녹내장치료제 식약처 임상1상 승인 pinotbio.com ↗
피노바이오가 식약처로부터 녹내장치료제 NTX-101의 국내 임상1상을 승인받았다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-23 | Pinotbio, Inc. | 피노바이오, 녹내장치료제 식약처 임상1상 승인 pinotbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05041543 ↗ |
| Route | Topical | “Eye drops, topical administration” NCT05041543 ↗ |